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were considered. Patients with CHF and an EF<40% were compared to those with CHF
and an EF>40% and to those with no CHF. The comparison of outcomes was stratified by
diabetes status and revascularization procedure. Results: Among patients with CHF,
those with low EF were significantly younger, less frequently had hypertension, but more
frequently had ECG abnormalities and triple vessel disease compared to those with
EF>40%. 
After adjusting for baseline clinical factors and revascularization procedure, the risk of 
long-term mortality was the greatest in patients with CHF and EF<40% (HR=3.33, 95% 
CI 2.31-4.78, p<0.01), but also significantly higher in patients with CHF and EF>40% 
(HR=1.66, 95% CI 1.31-2.10, p<0.01) than in patients with no CHF. The 9-year survival 
rate of diabetic patients with CHF and a low EF was extremely low at 22%. Conclusion: 
Among CHF patients undergoing revascularization, both low and normal EF significantly 
predict long-term survival. The absolute effect of CHF and low EF appears to be particu-
larly important among patients with diabetes.
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Background: Percutaneous coronary intervention (PCI) in patients with a history of con-
gestive heart failure (CHF) has been associated with worse outcomes. However, little is
know about these outcomes in the current era of improved CHF therapy and the wide-
spread use of coronary stents. Methods: Utilizing patients from the NHLBI 1985-1986
PTCA Registry and the Dynamic Registry (recruitment waves: 1997-1988, 1999 and
2001), we investigated differences in baseline risk factors, and acute and 1-year out-
comes in non-acute myocardial infarction patients with CHF undergoing their first PCI
during two different eras. This study sample is comprised of 117 CHF patients from the
1985-1986 PTCA Registry and 257 CHF patients enrolled in the Dynamic Registry.
Results: Compared to the 85-86 Registry, patients in the Dynamic Registry with CHF
were significantly older and had a higher prevalence of diabetes, prior CABG , triple ves-
sel CAD, and a lower mean EF, but had a higher lesion success rate after PTCA (92.6%
vs. 70.9%, p<0.001). In the Dynamic registry, stents were used in 77% of patients, and
there was a significantly higher use of ace inhibitors, aspirin, beta blockers, and statins.
The odds and risk ratios of adverse events in the Dynamic compared to PTCA registries
follow: 
Conclusions: While patients with CHF undergoing PCI in the current era have more
comorbidities and a lower EF, the in-hospital and long-term outcomes are markedly
improved. This is likely due to improved procedural success and improved medical ther-
apy.
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Background: Although coronary artery bypass graft surgery is often used to treat
patients with ischemic cardiomyopathy (ICM) and severe left ventricular systolic dysfunc-
tion (LVSD), data regarding percutaneous coronary intervention (PCI) with coronary
stenting in this high-risk patient population are very limited.
Methods: We retospectively evaluated consecutive patients with ICM and severe LVSD
(ejection fraction </= 35%) who underwent PCI with coronary stenting between 1/1/1995
and 12/30/2002. Patients with acute myocardial infarction (MI) were excluded. We com-
pared the frequency of in-hospital complications (in-hospital death, post-PCI MI, and
emergent CABG) in patients with severe LVSD (n=1274) and in patients with normal
LVEF (>/=50%) (n=6282) by univariate analysis. Predictors of in-hospital complications in
patients with severe LVSD were determined by multivariable logistic regression analysis.
Results: Baseline characteristics of patients with severe LVSD included age (68+/-11
years), gender (75% male), LVEF (28+/-7%), diabetes mellitus (39%), prior MI (69%),
and prior CABG (46%). The overall rate of in-hospital complications was higher for
patients with severe LVSD than for patients with normal LVEF (7.9% vs. 5.5%, p<0.001).
For patients with severe LVSD, in-hospital complication rates consisted of 2.2% in-hospi-
tal deaths, 5.9% post-PCI MIs, and 0.4% emergent CABG. Independent predictors of in-
hospital complications included NYHA class IV symptoms, ACC lesion type B2 or C,
renal insufficiency (serum creatinine > 2 mg/dL), and intended SVG intervention (all
p<0.05). In our study, 372 patients with severe LVSD (29%) had none of these risk fac-
tors. In the absence of these 4 risk factors, the in-hospital complication rate for patients
with severe LVSD was 3.5%.
Conclusions: Although patients with severe LVSD have an overall higher risk of in-hos-
pital complications following PCI with stenting, in the absence of several high-risk clinical
features, rates of in-hospital complications in patients with severe LVSD versus average
patients with normal LVEF are comparable.
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Background: Stent restenosis still occurs even in the drug eluting stent (DES) era.
IVUS-guided cutting balloon angioplasty (CB) before stenting would offer a favorable
long-term outcome similar to DES.
Methods: We randomly assigned 521 anginal patients to either CB before stenting (260
patients) or balloon angioplasty (POBA) before stenting (261 patients). IVUS guided pro-
cedures were performed in 279 (54%) patients. All patients were divided into 4 groups
according to devices before stenting and either IVUS- or Angio-guidance (IVUS-guided
CB-stent; 137 pts, Angio-guided CB-stent; 123 pts, IVUS-guided POBA-stent; 142 pts,
and Angio-guided POBA-stent; 119 pts). The primary angiographic endpoint was rest-
enosis (>50% at follow-up).
Results: Follow-up angiography was performed in 453 patients (87%). An average ves-
sel size was 2.80+0.47mm with no difference among 4 groups (p=ns). IVUS guided CB-
stent indicated the lowest restenosis rate (6.6%) in comparison with Angio-guided CB-
stent (17.9%, p<.01), IVUS-guided POBA-stent (19.8%, p<.01) and Angio-guided POBA-
stent (18.2%, p<.01). Reflecting this phenomenon, overall restenosis rate was signifi-
cantly lower in all CB-stent than all POBA-stent (11.8% versus 19.1%, p<.05). While
baseline vessel area (VA) and lumen area (LA) were similar between the IVUS-CB-stent
and IVUS-POBA-stent groups, LA immediately after CB or POBA before stenting
(5.29+1.61mm2 vs. 4.15+1.33mm2, p<.05), LA after stenting (7.39+2.29mm2 vs.
6.61+2.04mm2, p<.05) and LA at follow-up (5.26+2.82mm2 vs. 4.41+2.05, p<.05) were
consistently greater in IVUS-CB-stent than IVUS-POBA-stent. Multivariate logistic
regression analysis to evaluate the respective contributions of clinical, angiographic and
IVUS variables to restenosis indicated that use of POBA (not CB) before stenting, DM,
LAD lesion and smaller vessel area by IVUS were independent predictors for restenosis.
Conclusions: Greater lumen obtained by IVUS-guided CB could convey a favorable
long-term outcome. While among 4 groups IVUS-guided CB-stent indicated the lowest
restenosis rate (6.6%) similar to those obtained by DES, IVUS-guided CB-stent can be a
substitute for DES in some clinical settings.
Unadjusted 9-Year Survival by EF
No CHF CHF & EF_40% CHF & EF<40% 2-way
p-value
N 9-Yr Survival N 9-Yr Survival N 9-Yr Survival
All patients 2917 82% 167 56% 49 45% 0.07
No Diabetes 2451 84% 103 65% 31 58% 0.31
CABG 1000 85% 43 62% 19 63% 0.57
PTCA 1451 84% 60 67% 12 50% 0.48
Diabetes 466 68% 64 41% 18 22% 0.03
CABG 217 71% 30 52% 8 25% 0.04
PTCA 249 65% 34 32% 10 18% 0.25
In-Hospital Adjusted OR Dynamic vs PTCA Registry CI P Value
Death 0.35 (0.14-0.91) <0.05
CABG 0.09 (0.03-0.34) _0.001
Death/MI/CABG 0.18 (0.09-0.38) _0.001
1-Year Adjusted RR Dynamic vs PTCA Registry CI P Value
CABG 0.26 (0.12-0.56) _0.001
Death/MI/CABG 0.55 (0.36-0.85) <0.01
PCI after discharge/CABG 0.46 (0.28-0.75) <0.01
